Skip to main content
News & Announcements , Articles & Publications , Translational Pharmaceutics® , Dr. Asma Patel , Matt Paterson

Dr. Asma Patel and Matt Pa­terson contribute to Drug Development & Delivery's special feature, 'Outsourcing Formulation Development & Manufacturing'

icon 6

Translational Pharmaceutics® platform enhances drug development efficiency and decision-making, as highlighted as part of commentary from Quotient Sciences in recent Drug Development & Delivery's special feature on outsourcing.

Dr. Asma Patel, Vice President of Integrated Development Services, and Matt Pa­terson, Chief Strategy Officer and Head of Translational Pharmaceutics® platform, recently contributed to Drug Development & Delivery's special feature: "Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure."

When speaking on our Translational Pharma­ceutics® platform, Paterson says it is a disruptive approach to drug development that integrates drug product formulation and manufacturing with clinical testing, setting us apart from other industry providers. "The integration of services im­proves decision-making while reducing time and white space, so milestones can be achieved as efficiently as possible, shortening drug development timelines as a whole.”

Dr. Patel discusses how the platform ad­dressed a product development challenge for one client. She explains, “We worked on a project for Rigel Pharmaceuticals, which was develop­ing R552, a small molecule RIPK1 inhibitor for autoimmune and inflammatory disor­ders. Preclinical data showed potential sol­ubility issues and, therefore, the client wanted to evaluate a range of formula­tions for the first-in-human (FIH) study. Leveraging the Translational Pharmaceu­tics® platform, we conducted an adaptive FIH study to develop lipid and solid disper­sion (SDD) formulations to enhance solu­bility. These formulations underwent rapid, iterative testing, allowing for immediate adjustments and optimization.”

Read the full article here on Drug Development & Delivery's website.

"The integration of services [with the Translational Pharma­ceutics® platform] im­proves decision-making while reducing time and white space, so milestones can be achieved as efficiently as possible, shortening drug development timelines as a whole.” 
-Matt Pa­terson

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, John McDermott Quotient Sciences’ John McDermott Contributes to Pharmaceutical Outsourcing Oral Solid Dosage Roundtable By: John McDermott
Read More
News & Announcements, Articles & Publications, John McDermott Q&A with Quotient Sciences’ John McDermott: Exploring the Benefits of Partnering with a CRDMO By: John McDermott
Read More
News & Announcements, Articles & Publications, Translational Pharmaceutics®, Dr. Asma Patel, Matt Paterson Dr. Asma Patel and Matt Pa­terson contribute to Drug Development & Delivery's special feature, 'Outsourcing Formulation Development & Manufacturing' By: Dr. Asma Patel and Matt Paterson
Read More
Get in touch
Humanity can't afford to wait, so neither can we.